A citation-based method for searching scientific literature

Daniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, André M Murad, Salah-Eddin Al-Batran, David H Ilson, Sergei Tjulandin, Evengy Gotovkin, Boguslawa Karaszewska, Igor Bondarenko, Mohamedtaki A Tejani, Anghel A Udrea, Mustapha Tehfe, Ferdinando De Vita, Cheryl Turkington, Rui Tang, Agnes Ang, Yilong Zhang, Tien Hoang, Roger Sidhu, David Cunningham. Lancet Oncol 2017
Times Cited: 181



Eric Van Cutsem, Boguslawa Karaszewska, Yoon-Koo Kang, Hyun Cheol Chung, Veena Shankaran, Salvatore Siena, Ning F Go, Hui Yang, Marco Schupp, David Cunningham. Clin Cancer Res 2019
Times Cited: 40




List of shared articles



Times cited

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
1

Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim. Biomedicines 2022
2

Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities.
Emily Harrold, Lynda Corrigan, Simon Barry, Maeve Lowery. Expert Rev Gastroenterol Hepatol 2022
0

The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence.
Masae Iwasaki, Hailin Zhao, Cong Hu, Junichi Saito, Lingzhi Wu, Aislinn Sherwin, Masashi Ishikawa, Atsuhiro Sakamoto, Donal Buggy, Daqing Ma. Cell Biol Toxicol 2022
1

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Daniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M Chase, Bryan F Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart,[...]. Cancer Discov 2021
22

Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.
Danish Safi, Taher Abu Hejleh, Muhammad Furqan. Transl Lung Cancer Res 2021
1

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, Yelena Y Janjigian, Kohei Shitara. Nat Rev Clin Oncol 2021
27

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program.
Thomas Aparicio, Nathalie Cozic, Christelle de la Fouchardière, Emeline Meriaux, Jérome Plaza, Laurent Mineur, Rosine Guimbaud, Emmanuelle Samalin, Florence Mary, Thierry Lecomte,[...]. Target Oncol 2021
8

Targeting the Microenvironment in Esophageal Cancer.
Lei Wang, Huiqiong Han, Zehua Wang, Litong Shi, Mei Yang, Yanru Qin. Front Cell Dev Biol 2021
3

MET inhibitors in cancer: pitfalls and challenges.
Helena Oliveres, Estela Pineda, Joan Maurel. Expert Opin Investig Drugs 2020
10

Comprehensive review of targeted therapy for colorectal cancer.
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang. Signal Transduct Target Ther 2020
313

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress.
Valentina Gambardella, Tania Fleitas, Noelia Tarazona, Federica Papaccio, Marisol Huerta, Susana Roselló, Francisco Gimeno-Valiente, Desamparados Roda, Andrés Cervantes. J Clin Med 2020
9

Advances in targeted therapy for esophageal cancer.
Yan-Ming Yang, Pan Hong, Wen Wen Xu, Qing-Yu He, Bin Li. Signal Transduct Target Ther 2020
73